bluuebunny/crossref_metadata_2025_split huggingface dataset:
BASDAI and ASDAS disease states in relationship to ASAS40 response: post-hoc analysis of ixekizumab in radiographic axial spondyloarthritis
Authors: Rudwaleit Martin , Navarro-Compán Victoria , Russ Hagen , Panni Tommaso , Filippi Erica , Nassab Mani Haschemi , Liu-Leage Soyi , Goëb Vincent , Ciccia Francesco , Dudler Jean 
Published: January 2025

Abstract

Objectives
To explore the relationship between Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Axial Spondyloarthritis Disease Activity Score (ASDAS) used in clinical practice and the Assessment of SpondyloArthritis international Society 40 (ASAS40) response, the primary endpoint in clinical trials in axial spondyloarthritis (axSpA).

Methods
Data from COAST-V, a phase 3 trial of ixekizumab versuss placebo in biologic-naïve radiographic axSpA (r-axSpA) patients, were analysed. Patients treated with ixekizumab every 4 weeks were categorized using ASAS40 response at week 16 and 52. The association between BASDAI and ASDAS disease states, respectively and ASAS40 response achieved/not achieved was investigated. Additionally, back pain, fatigue, Bath Ankylosing Spondylitis Functional Index, ASAS Health Index, and 36-item Short Form Health Survey Physical Component Summary scores corresponding to these states were assessed. Results were reported descriptively.

Results
After 16 weeks, 48.1% (39/81) patients achieved an ASAS40 response. Among them 71.8% (n = 28) and 43.6% (n = 17) achieved BASDAI &lt; 3 and BASDAI &lt; 2, respectively; 76.9% (n = 30) and 33.3% (n = 13) attained ASDAS &lt; 2.1 and ASDAS &lt; 1.3, respectively. Among ASAS40 responders at week 52 (53.1%; 43/81), 83.8% (n = 36) and 51.2% (n = 22) patients achieved BASDAI &lt; 3 and BASDAI &lt; 2, respectively; 93.1% (n = 40) and 41.9% (n = 18) attained ASDAS &lt; 2.1 and ASDAS &lt; 1.3. Lower BASDAI and ASDAS disease states corresponded well with less back pain, fatigue, functioning impairment, and better health-related quality of life.

Conclusions
More than 70% of biologic-naïve r-axSpA patients who achieved an ASAS40 response, also attained low disease activity or inactive disease as measured by BASDAI or ASDAS. Findings may help clinicians translate results from clinical trials into daily practice.
Cross-trait GWAS in COVID-19 and systemic sclerosis reveals novel genes implicated in fibrotic and inflammation pathways
Authors: Rosa-Baez Carlos , Borrego-Yaniz Gonzalo , Rodriguez-Martin Inmaculada , Kerick Martin , Acosta-Herrera Marialbert , Martín Javier , Ortiz-Fernández Lourdes 
Published: January 2025

Abstract

Objectives
Coronavirus disease 2019 (COVID-19) and SSc share multiple similarities in their clinical manifestations, alterations in immune response and therapeutic options. These resemblances have also been identified in other immune-mediated inflammatory diseases where a common genetic component has been found. Thus, we decided to evaluate for the first time this shared genetic architecture with SSc.

Methods
For this study, we retrieved genomic data from two European-ancestry cohorts: 2 597 856 individuals from The COVID-19 Host Genetics Initiative consortium, and 26 679 individuals from the largest genomic scan in SSc. We performed a cross-trait meta-analyses including &gt;9.3 million single nucleotide polymorphisms. Finally, we conducted functional annotation to prioritize potential causal genes and performed drug repurposing analysis.

Results
Our results revealed a total of 19 non-HLA pleiotropic loci, including 2 novel associations for both conditions (BMP1 and PPARG) and 12 emerging as new shared loci. Functional annotation of these regions underscored their potential regulatory role and identified potential causal genes, many of which are implicated in fibrotic and inflammatory pathways. Remarkably, we observed an antagonistic pleiotropy model of the IFN signalling between COVID-19 and SSc, including the well-known TYK2 P1104A missense variant, showing a protective effect for SSc while being a risk factor for COVID-19, along with two additional novel pleiotropic associations (IRF8 and SENP7). Finally, our findings provide new therapeutic options that could potentially benefit both conditions.

Conclusion
Our study confirms the genetic resemblance between susceptibility to and severity of COVID-19 and SSc, revealing a novel common genetic contribution affecting fibrotic and immune pathways.
Energy requirements of growing small ruminants raised for meat production in contrasting climatic regions: a meta-analysis
Authors: Souza V C , Bougouin A , Archimede H , Adegbola A , Kebreab E 
Published: January 2025

Abstract
The objective of this meta-regression was to evaluate the influence of ruminant species, sex, and climatic regions on the metabolizable energy (ME) requirements for maintenance (MEm) and weight gain (MEg) in growing small ruminants raised for meat production across different climatic regions. Data included 655 and 337 treatment means from 173 and 99 studies on sheep and goats, respectively. Metabolizable energy intake (MEI; MJ/kg^0.75) was regressed against average daily gain (ADG; g/kg^0.75), with the study included as a random effect. The analysis found that MEm was not affected by species (P = 0.50), but MEg (MJ/g ADG) was significantly different between species (P = 0.02), with sheep requiring 0.032 (± 0.002) and goats 0.026 (± 0.002) MJ/g ADG. Sex did not affect MEm in either species (P ≥ 0.32). However, in goats, intact males had a greater MEg (P = 0.02) than females (0.030 ± 0.003 vs. 0.013 ± 0.006 MJ/g ADG). MEm was lower (P = 0.03) in small ruminants raised in subtropical regions (0.497 ± 0.046 MJ/kg^0.75) compared to those in semi-arid (0.600 ± 0.038 MJ/kg^0.75) and tended to be lower than those in arid regions (0.529 ± 0.050 MJ/kg^0.75). However, these differences disappeared when adjusting for maturity, diet composition, digestibility, or altitude. MEg was significantly higher (P &lt; 0.05) in animals raised in arid regions (0.032 ± 0.006 MJ/g ADG) compared to those in Mediterranean (0.009 ± 0.004 MJ/g ADG) or semi-arid regions (0.009 ± 0.004 MJ/g ADG) after adjusting for diet composition and digestibility. Similarly, ruminants in Mediterranean regions had lower MEg (0.019 ± 0.004 and 0.009 ± 0.004 MJ/g ADG) than those in tropical regions (0.033 ± 0.002 and 0.024 ± 0.002 MJ/g ADG), respectively after adjusting for maturity, diet composition, and digestibility. MEg in semi-arid regions was consistently lower than in tropical regions, regardless of the covariates tested. For predictive purposes, the global model exhibited the best accuracy (CCC = 0.57 and RSR = 0.79), comparable to the model derived specifically for the tropical region (CCC = 0.58 and RSR = 0.80). This meta-analysis provides a comprehensive evaluation of species-specific differences in ME requirements in small ruminants while recognizing the challenges posed by confounding effects and climatic variability inherent in global datasets. The analysis suggests that animals raised in tropical conditions may have lower MEm than current feeding systems that use data from temperate climates.
Whole blood exchange ameliorates acute hemolytic anemia by reducing inflammation and oxidative stress in rats
Authors: Pei Siya , Wang Yanjie , Yao Run , Zhang Zhimin , Yin Wenyu , Li Ning 
Published: January 2025

AbstractHemolytic anemia (HA) is characterized by massive destruction of red blood cells (RBCs) and insufficient oxygen supply, which can lead to shock, organ failure, even death. Recent studies have preliminarily demonstrated the therapeutic effectiveness of whole blood exchange (WBE) in the management of acute hemolytic anemia and exhibited potential for reducing the duration of corticosteroid treatment, while the underlying mechanism of WBE therapy was not investigated in preclinical study. Hence, we investigate the therapeutic mechanisms of WBE in HA through established continued WBE therapy in rats creatively. This study aims to examine the mechanism of WBE on phenylhydrazine hydrochloride‐induced hemolytic anemia in SD rats to aid the development of therapeutics for drug‐induced hemolytic anemia (DIHA). Research results demonstrated the efficacy of WBE therapy in reducing mortality and ameliorating anemia in DIHA, as evidenced by significant improvements in representative hematological parameters such as RBCs, hemoglobin, and lactate dehydrogenase levels. Additionally, WBE indicated the ability to suppress oxidative stress and inflammation, and it mitigated organ damage and biochemical function by stabilizing hepatic ferroportin levels and decreasing organ iron content. These results highlighted the effectiveness of WBE as an innovative treatment for HA, furnishing evidence to prioritize it over traditional blood transfusion for severe anemias.
Salvianolic acid A promotes bone‐fracture healing via balancing osteoblast and osteoclast differentiation
Authors: Cao Binhao , Wu Xiaoyong , Zhou Chengwei , Chen Hongyu , Xue Deting , Pan Zhijun 
Published: January 2025

AbstractNonunion is a significant complication in fracture management for surgeons. Salvianolic acid A (SAA), derived from the traditional Chinese plant Salviae miltiorrhizae Bunge (Danshen), exhibits notable anti‐inflammatory and antioxidant properties. Although studies have demonstrated its ability to promote osteogenic differentiation, the exact mechanism of action remains unclear. This study investigated the effects of various SAA concentrations on the osteogenic differentiation of mouse‐derived bone marrow mesenchymal stem cells (mBMSCs) and the osteoclastic differentiation of bone marrow‐derived macrophages. Our findings indicate that SAA promotes the osteogenic differentiation of mBMSCs in a concentration‐dependent manner, primarily by inhibiting the Notch1 signaling pathway. Notably, the administration of two Notch1 agonists (Jagged‐1 and VPA) inhibited the effects of SAA on osteogenic differentiation. Additionally, SAA facilitated the autophagic degradation of NICD1, further enhancing osteogenic differentiation. Furthermore, SAA also dose‐dependently inhibited the osteoclastic differentiation of bone marrow‐derived macrophages, which is linked to its suppression of NF‐κB signaling pathways. In a fracture model, SAA demonstrated a capacity to promote healing. In conclusion, SAA enhances bone fracture healing by balancing osteoblast and osteoclast differentiation.
Xuefu Zhuyu Decoction improves hyperlipidemia through the MAPK/NF‐κB and MAPK/PPARα/CPT‐1A signaling pathway
Authors: Han Jiajun , Miao Yuyang , Song Linze , Zhou Xianfeng , Liu Yan , Wang Lin , Zhu Kai , Ma He , Ma Yan , Li Qingjie , Han Dong 
Published: January 2025

AbstractXuefu Zhuyu Decoction (XZD) is widely used in the treatment of cardiovascular diseases. The purpose of this study was to explore the pharmacological effects and molecular mechanisms of XZD in improving hyperlipidemia and to provide a theoretical framework for clinical application. In this study, the signaling pathways regulated by XZD in improving hyperlipidemia were predicted by network pharmacology. Molecular docking was used to verify the affinity between the components in XZD and the target. Furthermore, a hyperlipidemic model in rats was constructed through feeding a high‐fat diet. The effect of XZD on hyperlipidemia was verified by histopathological staining, Elisa, and western blot. The results found that the XZD improved dyslipidemia and inflammatory factor disorders, and inhibited liver function damage, pathological damage, and oxidative stress damage in hyperlipidemic rats. The findings from molecular docking and network pharmacology suggested that the mechanism of XZD improving hyperlipidemia may be closely related to the MAPK, NF‐κB, and PPAR pathways. This study demonstrated that the XZD inhibited liver lipid metabolism disorder and inflammatory response by regulating the MAPK/NF‐κB and MAPK/PPARα/CPT‐1A pathway, significantly improved liver histopathological damage and oxidative stress injury, and played a protective role in hyperlipidemic rats.
Analysis of the Top Articles and Authors of the Journal of Orthopaedic Trauma and Bibliometric Comparison of Impact Factors of Orthopaedic Surgery Journals
Authors: Box McKenna W. , Puga Troy , Marsh Laurel , Beal Wrangler , Chandrasekaran Vinay , Riehl John T. 
Published: January 2025

OBJECTIVES:
To determine the top 100 cited authors and the top 20 articles in the Journal of Orthopaedic Trauma (JOT) and compare its impact factor to orthopaedic and non-orthopaedic surgery literature.

DESIGN:
Review

METHODS:
The Web of Science database was used to determine the top 100 cited authors and top 20 cited articles that originated in JOT from 1995 to the present. The total number of citations for each article and author in first, last, and any author position for publications in JOT, and the location of training and current place of work for each author were gathered. Each author's total number of citations as first author was tallied to determine the top 100 JOT first authors. The Journal Citation Reports database was searched to determine the impact factor (IF) of multiple orthopaedic and non-orthopaedic journals from 1997 to 2023. Yearly IF and yearly IF percent growth were calculated.

RESULTS:
The number of citations for the top 20 cited articles in JOT ranged from 302 to 787. Of the top 100 JOT first authors by citation number, 93 were orthopaedic surgeons. 65% of these completed a residency in the United States, 61% worked in the United States, and of the authors that work in the United States, 70.5% practice in an academic setting. From 1997 to 2023, JOT's mean yearly IF was 1.6, and the mean yearly IF percent growth was 6.1%. The mean IF for included comparison orthopaedic subspecialty journals was 2.3, with 5.6% mean yearly IF percent growth. JOT’s median IF was 1.8 and was second to Injury (IF 1.9) within orthopaedic trauma journals evaluated.

CONCLUSIONS:
This bibliometric analysis shows that JOT's most cited authors are primarily U.S.-trained orthopaedic surgeons in academic environments. JOT has consistently experienced annual growth in its impact factor throughout its almost 30-year history and has one of the highest impact factors of measured orthopaedic trauma journals.

LEVEL OF EVIDENCE:
IV
Diagnosis, Classifications and Treatment of Os Odontoideum
Authors: Alves Oscar L. , Lee June Ho , Kitumba Djamel , Lucas Agnaldo , Baeesa Saleh , Ben Ali Said , Sampaio Francisco , Uriza Gustavo , Gepp Ricardo , Zileli Mehmet , Botelho Ricardo , Klekamp Jörg , Goel Atul 
Published: January 2025

Study Design.
A systematic literature review and consensus using Delphi method.

Objective.
The aim was to formulate consensus recommendations regarding the natural history, diagnosis, classification and optimal treatment of Os Odontoideum with global applicability.

Summary of background.
Os odontoideum (OO) is a rare anomaly of the cranio-vertebral junction (CVJ). Due to the paucity of literature, there is still considerable debate about the clinical management of OO.

Material and Method.
Using PubMed, the authors reviewed the literature on OO published from 2011 to 2022. Using the Delphi method, a panel expert spine surgeons and members of the WFNS Spine Committee analyzed the strength of the published literature, elaborated and voted statements concerning diagnosis and management.

Result.
The diagnosis may be established incidentally. Symptoms may manifest as neck discomfort or encompass occipital-cervical pain, myelopathy, or vertebrobasilar ischemia. Diagnosis is usually made with plain radiographs and CT can. Dynamic x-rays identify C1-C2 instability whereas MRI assess spinal cord integrity and compression. Asymptomatic cases lacking radiologic instability are generally handled through regular observation and serial imaging, until predictors of neurological deterioration necessitate surgical intervention. In the event of atlantoaxial instability or neurological dysfunction, surgical intervention with instrumentation and fusion is required to maintain stability. In irreducible cases, C1-2 joint manipulation and distraction permits re-alignment and deformity correction avoiding decompression, either from anterior or posterior.

Conclusion.
The management guidelines for asymptomatic OO are still a grey zone as our understanding of the natural history is still vague. Therefore, we need more large-center studies to investigate this condition further. Whenever symptomatic, unstable or asymptomatic presenting with risk factors, OO is better managed with atlanto-axial fusion avoiding occipital inclusion in the construct. In irreducible OO, C1-2 joint manipulation and distraction is preferred to decompression.
Career Planning and Maintaining Well-being in Academic Plastic Surgery
Authors: Egan Katie , Aryanpour Zain , Kokosis George , Viennas Lambros K. 
Published: January 2025

Summary:
Success in academic plastic surgery is based on the traditional pillars of promotion: clinical excellence, teaching, research, leadership, and service to the university and community. The time commitment and workload for career advancement are highly demanding and, therefore, well-being is essential to avoid burnout. A congruent healthy work environment that meets institutional goals and surgeons’ objectives can be established through inclusive, transparent, strategic, and operational planning. In this Special Topic article, we will review the requisites and challenges to promotion in academic plastic surgery and will discuss longitudinal strategies for well-being during the early, middle, and late academic career.
Short-term starvation boosts anti-PD-L1 therapy by reshaping tumor-associated macrophages in hepatocellular carcinoma
Authors: Cheng Kun , Cai Ning , Yang Xing , Li Danfeng , Jinghan Zhu , Yang Hui Yuan , Liu Sha , Ning Deng , Liang Huifang , Zhao Jianping , Zhang Zhanguo , Zhang Wanguang 
Published: January 2025

Background and Aims:
Immune checkpoint inhibitors (ICIs) have revolutionized systemic hepatocellular carcinoma (HCC) treatment. Nevertheless, numerous patients are refractory to ICIs therapy. It is currently unknown whether diet therapies such as short-term starvation (STS) combined with ICIs can be used to treat HCC. This study aimed to investigate whether STS could sensitize HCC tumors to immunotherapy.

Approach and Results:
STS was found to attenuate tumor progression by inducing tumor-associated macrophages (TAMs) to switch to an antitumoral phenotype, enhancing phagocytosis of tumor cells, and stimulating subsequent anti-tumor immunity of CD8+ T cells as demonstrated in three HCC mouse models, NCG mice, and Rag2-KO mice. Furthermore, STS combined with anti-PD1/L1 suppressed tumor progression, while the efficacy of anti-programmed cell death 1 ligand 1 (PD-L1) was improved when combined with STS. Mechanistically, TAM-derived exosomal PD-L1 (exoPD-L1) impairs the efficacy of anti-PD-1/L1. STS attenuates exoPD-L1 secretion from TAM by regulating the fructose diphosphatase 1 (FBP1) /Akt/Rab27a axis. Modulating FBP1/Akt/Rab27a axis potentiates the anti-PD-L1 response using two liposomal delivery systems and macrophage adoptive transfer.

Conclusions:
This study describes the immunomodulatory effects of STS and provides a rationale for its application as an adjuvant in HCC immunotherapy.
Clinical outcomes and care for spontaneous bacterial peritonitis: A national cohort study
Authors: Serper Marina , Tang Helen , Zhang Siqi , McCullough Alexandra , Kaplan David E. , Taddei Tamar H. , Mahmud Nadim 
Published: January 2025

Background & Aims:
SBP leads to high rates acute kidney injury (AKI) -hepatorenal syndrome and mortality. Population-based studies on contemporary SBP epidemiology are needed to inform care. In a large, national cohort of patients diagnosed with SBP and confirmed by ascitic fluid criteria, we characterized ascitic fluid characteristics, in-hospital and 12-month mortality, AKI, and recurrent SBP.

Approach & Results:
We investigated how individual and bundled quality measures for SBP associated with outcomes after multi-level adjustment for health-system, patient clinical factors and quality measures. Individual and bundled quality metrics were inpatient antibiotics within 48 hours, intravenous albumin, repeat paracentesis within 48 hours, recognition of SBP, and prophylactic antibiotics upon discharge. Among 4,330 patients with newly diagnosed SBP, in-hospital mortality was 15.5% and 12-month mortality was 56.6%. The incidence of Stage 1 AKI was 26.6%, 15.7% for Stage 2, and 22.8% for Stage 3. The cumulative incidence of recurrent SBP was 10.3%. Guideline-recommended albumin was the only individual metric associated with reduced in-hospital mortality (HR 0.73, 95%CI 0.59 - 0.91). Receipt of a higher number of metrics from the SBP bundle was associated with progressively lower 12-month post-discharge mortality: patients who received 3, 4, and 5 SBP bundle components had 20%, 38%, and 56% lower hazard of mortality, respectively, relative to those receiving 2 or fewer (all p<0.001). The SBP bundle was associated with lower incidence of Stage 3 versus Stage 0-2 AKI (OR 0.66, 95%CI 0.51-0.86).

Conclusion:
Prospective implementation of evidence-based SBP bundles may improve care outcomes and mortality in SBP.
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis
Authors: Desplats Victor , Haudebourg Luc , Verger Nicolas , Assaraf Julie , Mouri Sarah , Bouzbib Charlotte , Bonnefont-Rousselot Dominique , Alkouri Rana , Sakka Mehdi , Sultanik Philippe , Leproux Apolline , Weiss Nicolas , Rudler Marika , Thabut Dominique 
Published: January 2025

Background and Aims:
In cirrhosis, some patients display acute encephalopathy without hyperammonemia (NonHep E) which is not considered as overt hepatic encephalopathy (OHE). We aimed to assess the prevalence and characteristics of NonHep E and OHE in patients with cirrhosis displaying acute encephalopathy, assess their respective prognosis and compare it to other causes of acute decompensation with/without hyperammonemia.

Approach and Results:
We conducted a retrolective analysis from a prospective cohort of patients hospitalized for acute decompensation. Hyperammonemia was defined by NH3 >50 µmol/L. Patients were divided into 4 groups: OHE (encephalopathy and NH3 >50 µmol/L: group 1), NonHep E (encephalopathy and NH3≤50 µmol/L, group 2), and 2 control groups with acute decompensation/without encephalopathy (NH3≤50 µmol/L [group 3] or NH3>50 µmol/L [group 4]). Five hundred thirty patients were included (168 group 1, 76 group 2, 125 group 3, and 161 group 4). Overall, 168/244 (69%) of patients with acute encephalopathy displayed OHE, and 76/244 (31%) NonHep E. NonHep E patients were significantly more exposed to medications than patients with OHE. One-year transplant-free survival was 60.4%. In multivariable analysis, compared to patients with normal ammonemia and without encephalopathy, OHE was independently associated with a lower 1-year transplant-free survival (1.58 [95% CI: 1.14–2.18, p=0.006]). Patients with OHE did not display a higher risk of death or transplantation than NonHep E patients (HR: 1.27, 95% CI: 0.91–1.77, p=0.161).

Conclusions:
NonHep E accounts for one-third of admissions for acute encephalopathy and displays as severe a prognosis as OHE. OHE is independently associated with lower transplant-free survival at 1 year.